Fig. 4.

Apocynin prevents the cardiac enlargement and improves cardiac function in cardiac cardiac-specific hD5^F173-TG mice (hD5^F173L). A: Representative echocardiograms of 4-month-old cardiac-specific hD5^F173L-TG mice treated with saline (hD5^F173L + Saline) or apocynin (APO, 1 mmol/kg/day) (hD5^F173L + APO) for 4 weeks, starting at 3 months of age (n = 10 mice/group). B: Heart size and weight. C–F: Echocardiographic analysis of cardiac volume and function. (n = 10 mice/group); *P < 0.05 vs. hD5^F173 + Saline. EF = ejection fraction, FS = fractional shortening.